Imagen de Portada

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Xinli Chen, Wenjun Wang, Jianyu Lv
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Distinct Challenges of Paediatric From Adult‐Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children
por: Alessandro Molinaro, et al.
Publicado: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
por: Christian P. Selinger, et al.
Publicado: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
por: Guofu Mao, et al.
Publicado: (2026)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
por: Xueneng Yang, et al.
Publicado: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
por: Alice S. Day, et al.
Publicado: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
por: Luisa Bertin, et al.
Publicado: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
por: Chachrit Khunsriraksakul, et al.
Publicado: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
por: Arta Aliu, et al.
Publicado: (2024)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
por: Luisa Bertin, et al.
Publicado: (2026)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
por: Adam S. Faye, et al.
Publicado: (2025)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
por: Jakob B. Seidelin
Publicado: (2024)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
por: Jialing Wang, et al.
Publicado: (2025)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis
por: Saverio Pochesci, et al.
Publicado: (2026)

Editorial: Getting to the Heart of the Matter in IBD
por: Ashwin N. Ananthakrishnan
Publicado: (2025)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis. Authors' Reply
por: Pierfrancesco Visaggi, et al.
Publicado: (2026)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
por: Ramin Ebrahimi, et al.
Publicado: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
por: Daniele Noviello, et al.
Publicado: (2025)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
por: Merle Claßen, et al.
Publicado: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
por: Amanda Ricciuto, et al.
Publicado: (2024)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
por: Vincenzo Stranges, et al.
Publicado: (2025)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
por: Wenjun Meng, et al.
Publicado: (2024)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
por: Shlomi Cohen, et al.
Publicado: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
por: Darcy Quinn Holt, et al.
Publicado: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
por: James L. Alexander, et al.
Publicado: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
por: Parul Tandon, et al.
Publicado: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
por: Jee‐Fu Huang, et al.
Publicado: (2026)

Early‐Life Infections, Antibiotics and Later Risk of Childhood and Early Adult‐Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts
por: Karl Mårild, et al.
Publicado: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
por: Tamar Schildkraut, et al.
Publicado: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
por: Jiru Li, et al.
Publicado: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
por: Giovanni Cammarota, et al.
Publicado: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
por: Maria Ling Lundström, et al.
Publicado: (2024)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
por: Keith Bodger
Publicado: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
por: Shabari Shenoy, et al.
Publicado: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
por: Muhammad Osama, et al.
Publicado: (2024)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
por: Kuan‐Ju Lin, et al.
Publicado: (2025)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
por: Finlay Macrae
Publicado: (2025)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
por: Fahim Ebrahimi, et al.
Publicado: (2024)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
por: Katherine L. Stone, et al.
Publicado: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
por: Olga M. Nardone, et al.
Publicado: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
por: Manjeet Kumar Goyal, et al.
Publicado: (2026)